Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 2, 2007, Pages 185-193

  Dillman, Robert O ^a   Schreeder, Marshall T ^b   Hon, Jeremy K ^b   Connelly, Elizabeth F ^c   DePriest, Carol ^a   Cutter, Kathy ^b  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Comprehensive Cancer Institute ^*  (United States)

^c Clinical Hematology/Oncology Services Inc   (United States)

Author keywords

Biochemotherapy; Chronic lymphocytic leukemia (CLL); PCR; Pentostatin; Rituximab

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; PARACETAMOL; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CARDIOTOXICITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; DEATH; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RIGOR; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; DELIVERY OF HEALTH CARE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PENTOSTATIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34250860682     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.332     Document Type: Article

References (29)

1. Chiorazzi N, Rai KR, Farrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804.
2. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7:433.
3. Ho AD, Thaler I, Stryekmans F, et al. Pentostatin in refractory chronic lymphocytic leukemia: A phase 11 trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990;82:1416.
4. Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991;9:44.
5. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695.
6. Piro LD, Carrera CJ, Beutler E, et al. 2-chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069.
7. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153.
8. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165.
9. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326.
10. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:3554.
11. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768.
12. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750.
13. Eichhorst BF, Bush R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885.
14. Flinn IW, Kumm E, Grever MR, et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. [abstr. #475] Blood 2004;104:139a.
15. Byrd JC, Peterson B, Morrison VA, et al. Randomized phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6.
16. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49.
17. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070.
18. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4079.
19. Dillman RO. Pentostatin (Nipent®) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Exp Rev Anticancer Ther 2004;4:27.
20. Duggan DB, Anderson JR, Dillman RO, et al. 2′Deoxycoformycin [pentostatin] for refractory non-Hodgkin's lymphoma: A CALGB phase II study. Med Ped Oncol 1990;18:203.
21. Oken MM, Lee S, Kay NE, et al. Pentostatin, chlorambucil, and prednisone therapy for B-chronic lymphocytic leukemia: A phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymph 2004;45:79.
22. Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003;21:1278.
23. Drapkin R, Di Bella NJ, Cuasay LC, et al. Phase II multicenter trial of pentostatin and rituximab in patients with previously treated or untreated chronic lymphocytic leukemia. (abstr. #3171) Blood 2002;100:803a.
24. Cheson B, Bennett J, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990.
25. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244.
26. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46: 219.
27. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24: 1575.
28. Kay NE, Geyer S, Call T, et al. Combination chemoimmunotherapy with pentostatin, cyclophsophamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. [abstr. 35] Blood 2006:108:15a.
29. Shanafelt TD, Byrd JC, Geyer SM, et al. The pentostatin, cyclophosphamide, and rituximab regimen is highly active and well tolerated regardless of patient age, creatinine clearance, and performance status: Analysis of a multicenter phase II trial. [abstr. #36] Blood 2006:108:15a.